Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, GSK plc (GSK) has a Wall Street consensus price target of $53.00, based on estimates from 29 covering analysts. With the stock currently trading at $59.13, this represents a potential downside of -10.4%. The company has a market capitalization of $118.65B.
Analyst price targets range from a low of $53.00 to a high of $53.00, representing a 0% spread in expectations. The median target of $53.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 9 analysts rating the stock as a Buy or Strong Buy,16 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, GSK trades at a trailing P/E of 16.2x and forward P/E of 12.3x. Analysts expect EPS to grow +72.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $53.41, with bear and bull scenarios of $26.04 and $87.40 respectively. Model confidence stands at 55/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how GSK stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonGSK's consensus price target is $53, -10.4% below the current price of $59.13. The 29 analysts tracking GSK see downside risk at present valuations.
GSK has a consensus rating of "Hold" based on 29 Wall Street analysts. The rating breakdown is mixed, with 16 Hold ratings making up the largest segment. The consensus 12-month price target of $53 implies -10.4% downside from current levels.
With a forward P/E of 12.2615x, GSK trades at a relatively low valuation. The consensus target of $53 implies -10.4% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $53 for GSK, while the most conservative target is $53. The consensus of $53 represents the median expectation. Our quantitative valuation model projects a bull case target of $87 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
GSK is heavily covered by Wall Street, with 29 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 16 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GSK stock forecast based on 29 Wall Street analysts shows a consensus price target of $53, with estimates ranging from $53 (bear case) to $53 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $53, with bear/bull scenarios of $26/$87.
Our quantitative valuation model calculates GSK's fair value at $53 (base case), with a bear case of $26 and bull case of $87. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 55/100.
GSK trades at a forward P/E ratio of 12.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 16.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on GSK, with 4 Sell ratings and a price target of $53 (-10.4% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GSK analyst price targets range from $53 to $53, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $53 consensus represents the middle ground. Our model's $26-$87 range provides an independent fundamental perspective.